CSTL
Price
$34.96
Change
-$3.98 (-10.22%)
Updated
Feb 4 closing price
Capitalization
1.02B
27 days until earnings call
Intraday BUY SELL Signals
EXAS
Price
$102.27
Change
-$0.24 (-0.23%)
Updated
Feb 4 closing price
Capitalization
19.42B
19 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CSTL vs EXAS

Header iconCSTL vs EXAS Comparison
Open Charts CSTL vs EXASBanner chart's image
Castle Biosciences
Price$34.96
Change-$3.98 (-10.22%)
Volume$668.32K
Capitalization1.02B
Exact Sciences
Price$102.27
Change-$0.24 (-0.23%)
Volume$2.71M
Capitalization19.42B
CSTL vs EXAS Comparison Chart in %
View a ticker or compare two or three
VS
CSTL vs. EXAS commentary
Feb 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CSTL is a StrongBuy and EXAS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 05, 2026
Stock price -- (CSTL: $34.96 vs. EXAS: $102.27)
Brand notoriety: CSTL: Not notable vs. EXAS: Notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: CSTL: 177% vs. EXAS: 79%
Market capitalization -- CSTL: $1.02B vs. EXAS: $19.42B
CSTL [@Medical Specialties] is valued at $1.02B. EXAS’s [@Medical Specialties] market capitalization is $19.42B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $12.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CSTL’s FA Score shows that 0 FA rating(s) are green whileEXAS’s FA Score has 0 green FA rating(s).

  • CSTL’s FA Score: 0 green, 5 red.
  • EXAS’s FA Score: 0 green, 5 red.
According to our system of comparison, both CSTL and EXAS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CSTL’s TA Score shows that 5 TA indicator(s) are bullish while EXAS’s TA Score has 2 bullish TA indicator(s).

  • CSTL’s TA Score: 5 bullish, 4 bearish.
  • EXAS’s TA Score: 2 bullish, 5 bearish.
According to our system of comparison, CSTL is a better buy in the short-term than EXAS.

Price Growth

CSTL (@Medical Specialties) experienced а -11.52% price change this week, while EXAS (@Medical Specialties) price change was +0.02% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -3.67%. For the same industry, the average monthly price growth was -1.52%, and the average quarterly price growth was +22.39%.

Reported Earning Dates

CSTL is expected to report earnings on Mar 04, 2026.

EXAS is expected to report earnings on Feb 24, 2026.

Industries' Descriptions

@Medical Specialties (-3.67% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EXAS($19.4B) has a higher market cap than CSTL($1.02B). EXAS YTD gains are higher at: 0.699 vs. CSTL (-10.129). CSTL has higher annual earnings (EBITDA): 24M vs. EXAS (-732.26M). EXAS has more cash in the bank: 1B vs. CSTL (288M). CSTL has less debt than EXAS: CSTL (37.1M) vs EXAS (2.52B). EXAS has higher revenues than CSTL: EXAS (3.08B) vs CSTL (344M).
CSTLEXASCSTL / EXAS
Capitalization1.02B19.4B5%
EBITDA24M-732.26M-3%
Gain YTD-10.1290.699-1,449%
P/E Ratio30.24N/A-
Revenue344M3.08B11%
Total Cash288M1B29%
Total Debt37.1M2.52B1%
FUNDAMENTALS RATINGS
CSTL vs EXAS: Fundamental Ratings
CSTL
EXAS
OUTLOOK RATING
1..100
8272
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
52
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9197
PRICE GROWTH RATING
1..100
4137
P/E GROWTH RATING
1..100
99100
SEASONALITY SCORE
1..100
n/a90

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EXAS's Valuation (52) in the Biotechnology industry is in the same range as CSTL (58) in the null industry. This means that EXAS’s stock grew similarly to CSTL’s over the last 12 months.

EXAS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CSTL (100) in the null industry. This means that EXAS’s stock grew similarly to CSTL’s over the last 12 months.

CSTL's SMR Rating (91) in the null industry is in the same range as EXAS (97) in the Biotechnology industry. This means that CSTL’s stock grew similarly to EXAS’s over the last 12 months.

EXAS's Price Growth Rating (37) in the Biotechnology industry is in the same range as CSTL (41) in the null industry. This means that EXAS’s stock grew similarly to CSTL’s over the last 12 months.

CSTL's P/E Growth Rating (99) in the null industry is in the same range as EXAS (100) in the Biotechnology industry. This means that CSTL’s stock grew similarly to EXAS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CSTLEXAS
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
71%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
71%
Momentum
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
79%
MACD
ODDS (%)
Bearish Trend 1 day ago
87%
N/A
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
69%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
79%
Bullish Trend 1 day ago
70%
Advances
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 3 days ago
70%
Declines
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 9 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
62%
Aroon
ODDS (%)
Bullish Trend 4 days ago
88%
Bullish Trend 1 day ago
69%
View a ticker or compare two or three
Interact to see
Advertisement
CSTL
Daily Signal:
Gain/Loss:
EXAS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EQNUX23.290.07
+0.30%
MFS Equity Income R4
WBCCX9.850.01
+0.10%
TETON Westwood Balanced C
FHKIX59.90N/A
N/A
Fidelity Advisor China Region I
EIRAX16.12-0.07
-0.43%
Eaton Vance All Asset Strategy I
GFDDX86.49-1.22
-1.39%
Invesco Global R5

CSTL and

Correlation & Price change

A.I.dvisor indicates that over the last year, CSTL has been loosely correlated with NTRA. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if CSTL jumps, then NTRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CSTL
1D Price
Change %
CSTL100%
-10.22%
NTRA - CSTL
60%
Loosely correlated
-9.69%
ILMN - CSTL
58%
Loosely correlated
-0.92%
BNR - CSTL
54%
Loosely correlated
-1.82%
TCMD - CSTL
50%
Loosely correlated
-2.09%
CDNA - CSTL
48%
Loosely correlated
-8.24%
More

EXAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, EXAS has been loosely correlated with ILMN. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if EXAS jumps, then ILMN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXAS
1D Price
Change %
EXAS100%
-0.23%
ILMN - EXAS
66%
Loosely correlated
-0.92%
BNR - EXAS
59%
Loosely correlated
-1.82%
CSTL - EXAS
56%
Loosely correlated
-10.22%
GH - EXAS
56%
Loosely correlated
-6.10%
QGEN - EXAS
55%
Loosely correlated
-0.35%
More